Abivax SA (ABVX) Stock Forecast & Price Target

Abivax is viewed positively because obefazimod has shown durable, clinically meaningful efficacy in Phase 3 ABTECT maintenance, including strong results in induction non-responders, while the comprehensive safety review suggests the malignancy findings are consistent with the underlying ulcerative colitis population rather than a clear drug-related signal. The company also appears financially de-risked in the near term, ending 1H26 with €1,169.5M in pro forma cash and guiding that this should fund operations into 4Q29, which supports continued execution through key catalysts such as the UC NDA filing expected in 4Q26 and Crohn’s disease data expected in mid-2027. Fundamentally, the investment case is strengthened by obefazimod’s differentiated microRNA-based mechanism, potential utility in patients who have failed IL-23-directed or multiple prior therapies, the removal of the royalty overhang, and the prospect of additional upside from combination therapy programs and next-generation pipeline assets.

Abivax is fundamentally risky despite the encouraging obefazimod data because the company remains a clinical-stage, single-segment R&D business with no marketed products, leaving its value dependent on one program advancing successfully through Phase 3 and beyond. While maintenance efficacy in UC was strong—with 52wk pbo-adjusted clinical remission of 39.3% and 40.3% at 25mg and 50mg, respectively, and pbo-adjusted endoscopic maintenance rates of 31.4% and 37.8%—these results still reflect an early commercialization path and do not eliminate the binary clinical, regulatory, and execution risks inherent in biotechnology development. The data are promising, including sustained responses after dose escalation to 50mg and broad improvements across key endpoints, but the company’s lack of diversification across products or revenue streams means setbacks in obefazimod would likely have an outsized negative impact on the stock.